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Abstract
Recent advances in tumor biology led to the realization that, in order to understand the mechanisms involved in
proliferation and invasion of tumor cells, an analysis of the complex interactions that tumor cells establish with
host cells of tumor microenvironment is required. The bidirectional interactions between tumor cells and compo-
nents of tumor microenvironment, in particular endothelial cells, cells of monocyte/macrophage lineage and fibro-
blasts/myofibroblasts, play a critical role in most of the events that characterize tumor progression and metastasis.
Interactions between these “reactive” normal cells and the genetically altered tumor cells, by either cell-to-cell con-
tacts or soluble mediators, control the most aspects of tumor formation and progression. This review addresses
some of the experimental evidences documenting that tumor cells may influence host cells of their own microen-
vironment by triggering changes that facilitate their local as well as distant dissemination. Therefore, it focuses on
macrophages and fibroblasts that, upon stimulation by tumor cells, change their state towards a tumor-promoting-
like phenotype.
Cancer as a non-homogeneous mass
Most primary tumors can be treated successfully by
surgery alone or in combination with chemotherapy,
immunotherapy or radiotherapy. However, the treat-
ment of disseminating tumors, once they have spread to
secondary sites, is a much more difficult task. Effective
treatment of multiple metastatic lesions by surgery or
radiotherapy is usually impossible due to their distribu-
tion in vital organs. Tumor cell invasiveness and metas-
tasis occur by a complex series of events in which
malignant cells invade host tissues, penetrate into body
cavities, lymphatic and/or blood circulatory systems.
Subsequently they disseminate to distant sites where
they invade into new surrounding tissues and proliferate
to form secondary tumors [1-3]. Metastatic diffusion of
cancer cells remains the most important clinical pro-
blem, and malignancy is represented by the ability of
tumor cells to invade adjacent host tissue at the primary
site and then to diffuse and colonize secondary organs.
Epidemiological and experimental evidences suggest
that a wide variability exists in the metastatic spread of
different human malignancies, but even cancers of
the same histological type often produce quite diverse
disease progression and survival outcomes for individual
patients [4]. This suggests that even in the same histolo-
gical class of cancer, the expected incidence and locali-
zation of metastatic lesions is not completely certain
[4,5].
The capacity of cancers to evolve and change during
their development has been termed “tumor pro-
gression” by L. Foulds (1954) [6]. The biological char-
acteristics that define tumor progression have been
extensively described, although the underlying mechan-
isms are still not completely defined. Tumor cells,
during their sometimes decade-long development,
accumulate increasingly genetic alterations, which are
typically generated by random mutational events,
finally allowing them to assume all the characteristics
of an invasive and metastatic cancer. In concert with
this “genetic instability”, a key role in favouring
genetic/epigenetic changes in tumor cells is played by
local as well as systemic host factors [7-9]. It has been
demonstrated that metastatic dissemination can be
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influenced by diet [10-13], the neuro-endocrine state
[14] and inflammatory-reparative processes [15-17].
Among the local factors, particular attention has been
devoted to the interactions that tumor cells establish
with various noncancerous types of cells that reside in
or are attracted to the tumor microenvironment. In
particular, the interaction of tumor cells with platelets
[18], lymphocytes [19], polymorphonuclear cells
[20,21], fibroblasts [22-25] and monocytes/macro-
phages was proved to be relevant to tumor progression
[26,27]. Under certain conditions, stromal cells may
inhibit tumor growth, but in other cases, they can sti-
mulate the growth and invasiveness of tumor cells.
Therefore, host cells, mainly in proximity to tumor
cells, may markedly alter tumor growth and invasive-
ness. A bidirectional interaction between tumor cells
and host cells, is now recognized as crucial for the
decision of whether tumor cells progress toward meta-
static dissemination or whether they remain dormant
[28,29]. Numerous bioactive agents such as proteins of
the extracellular matrix, growth factors, cytokines, che-
mokines and other molecules secreted by host cells
contribute to the evolution of tumor cells, including
the generation of a metastatic phenotype. It is hence
important to recognize that tumors, like normal tis-
sues, are dependent on the formation of a reactive
stroma. Nicolson has postulated that the acquisition of
a malignant phenotype in tumor cells may be related
in part to a phenotypic switch promoted by the host
environment and related to quantitative transcriptional
or translational changes, resulting in a transient altera-
tion in the concentrations of biologically active pro-
ducts [30]. Thus, both irreversible genetic alterations
and transient phenotypic properties contribute to the
generation of a malignant phenotype.
Although additional interactions will almost certainly
be discovered and the significance of these interactions
will be elucidated, it is already at present well accepted
that the reactive stroma of cancers is usually associated
with increased numbers of fibroblasts, enhanced capil-
lary density and the deposition of a new extracellular
matrix that is rich in type-1-collagen and fibrin. Circu-
lating monocytes are also recruited to the reactive
stroma in response to the tumoral chemotactic factors
and the wound healing-like processes occuring during
tumor growth. Tumor-associated macrophages derived
from differentiated monocytes and resident macro-
phages represent the major component of host leuko-
cytes that infiltrate tumor tissues.
This review focuses on the cancer progression towards
invasiveness and metastatic spread, taking into consid-
eration the biological role expressed by the so-called
“tumor-associated macrophages” (TAM) and “cancer-
associated fibroblasts” (CAF).
Tumor cell - macrophage interactions
The monocyte/macrophage lineage constitutes a large
portion of tumor infiltrating host cells. They enter into
the tumor mass via blood vessels throughout the life
span of tumors, from early-stage nodules just beginning
to vascularise to late-stage tumors that are invasive and
metastatic [31,32]. A number of tumoral chemoattrac-
tants ensure this recruitment, including colony-stimulat-
ing factor-1 (CSF-1, also known as M-CSF) [33,34], CC
chemokines [35] and vascular endothelial growth factor
(VEGF) [36].
Two major lines of evidence connect macrophages
and cancer: Firstly the association of chronic inflamma-
tion, that leads to macrophage accumulation, with can-
cer initiation and promotion [15-17]; secondly a high
density of TAM correlates with poor prognosis in over
80% of studies [37]. TAM accumulate in critical areas of
tumors, such as the hypoxic areas, and hypoxia triggers
a pro-angiogenic program in these cells [38]. Hypoxia
characterizes the microenvironment of many solid
tumors and it has been shown to affect many biological
properties of host cells as well as tumor cells that are
implicated in tumor growth and metastatic dissemina-
tion, e.g. the switch from oxidative to glycolytic metabo-
lism, the production of vascular endothelial growth
factors and protease activities [39,40].
Macrophages are remarkable for the diverse activities
in which they can engage on different occasions. Many
of these activities appear to be opposing each other:
pro-inflammatory vs anti-inflammatory, immunogenic vs
tolerogenic, and tissue destructive vs tissue reparative
processes. In particular, we know that macrophages
from healthy or inflamed tissues are capable of lysing
tumor cells, presenting tumor-associated antigens to
T-cells and expressing stimulatory cytokines for T- and
NK-cells [41]. On the other hand, macrophages isolated
from experimental as well as spontaneous tumors show
a reduced level of cytotoxic activities [26,27]. Clearly,
macrophages are multifunctional cells that “adapt”
themselves to the stimuli that prevail at the site to
which they have been attracted [42]. Quiescent macro-
phages of tissues (resident macrophages) respond to
immune or bacterial stimuli by expressing new func-
tional activities, resulting in their capacity to recognize
and destroy transformed cells (activated macrophages).
During this transition, macrophages may express a num-
ber of discrete phenotypic changes characterized by
specific functional activities. It is possible, that the con-
trasting effects exerted by TAM on the growth and
metastatic diffusion of tumor cells may reflect different
states of activation acquired by macrophages in the
tumoral microenvironment. The plasticity of macro-
phages may be exploited by tumor cells to elicit distinct
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functions at different stages of tumor progression. It is
also possible that multiple subpopulations of TAM exist
within a tumor mass, and these may change during
tumor development and on the basis of their location.
Mantovani et al. propose that TAM switch into polar-
ized type II or M2 macrophages [43]. These cells sup-
press T-cell activity and have poor antigen-presenting
capacity, promote proliferation through arginase, angio-
genesis and tissue repair (Figure 1), in contrast to classi-
cally activated type I or M1 macrophages that are able
to kill microorganisms and tumor cells [43]. The signals
that lead to the M2 polarization of TAM are not yet
completely understood, but IL-10 and TGFb might play
a role [44]. However, a transcriptome analysis of TAM
from a mouse fibrosarcoma showed an expression pro-
file of genes that appears to be mostly M2, but with
some M1 traits [45]. Sica and Bronte (2007) suggest that
a switch from the M1 to the M2 phenotype in TAM
might parallel the different interactions that take place
between tumor cells and macrophages during tumor
progression [46].
The contrasting effects of TAM are well exemplified
by the macrophage L-arginine metabolism. Macrophages
utilize L-arginine to synthesize nitric oxide (NO) with
the help of inducible NO synthase (iNOS), and to pro-
duce L-ornithine through arginase activity. While NO
may contribute to macrophage-driven tumoricidal activ-
ities, the polyamines derived from L-ornithine are essen-
tial nutrients for tumor cell proliferation [47]. Thus, the
balance between iNOS and arginase activity in TAMs
might be critical for tumor progression [48,49]. In addi-
tion, arginase can down-regulate NO production by
decreasing the intracellular arginine concentration, and
low concentrations of NO may act as part of a signalling
cascade for neovascularisation [50]. Thus, it was sug-
gested that NO can have pro- or anti-tumor actions,
depending on the local concentration of the molecule.
A tumor mass cannot grow beyond 2-3 mm3 in size
without angiogenesis. Neovascularization provides an
increased supply of nutrients and oxygen, and facilitates
the dissemination of tumor cells to distant organs. Most
solid tumors pass through two phases of growth: the
avascular phase and the vascular phase, when new capil-
laries penetrate the tumor and it begins to massively
grow and invade. Using transgenic mice susceptible to
mammary cancer, Lin et al. (2006) demonstrated that a
reduction of macrophage infiltration delayed the angio-
genic switch and the malignant transition of tumor cells
[51]. On the other hand, overexpression of CSF-1 in
wild-type mice that leads to an early induction of
macrophage infiltration into premalignant lesions
accompanied by neoangiogenesis, accelerates their tran-
sition to malignancy [52]. Vascular endothelial growth
factor (VEGF), a key player in the angiogenesis process,
is expressed by both tumor cells and TAM in several
histological types of human tumors [53]. In addition,
TAM-derived inflammatory cytokines (IL-1b, TNFa)
may stimulate tumor cells to enhance the production of
VEGF [54], and to produce angiogenin, a potent proan-
giogenic protein [55]. VEGF may become also available
in the tumor microenvironment through the release of
matrix metalloprotease-9 (MMP-9) by TAM [56].
Recently, Giordano et al. demonstrated that TAM are
the most important cell type producing semaphorin 4 D
within tumor stroma, a molecule required for angiogen-
esis and vessel maturation [57]. Therefore, TAM are cri-
tical in tumor angiogenesis, an essential step in tumor
progression and metastatic dissemination [58].
Figure 1 Some biological activities of polarized M2 macrophages.
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Moreover, using a intravital multiphoton microscopy,
Wyckoff et al. (2007) observed that tumor cell intravasa-
tion in mammary tumors occurs in association with
perivascular macrophages [59], and Ojalvo et al. (2010)
demonstrated that this subset of the macrophage popu-
lation is particularly enriched for molecules involved in
Wnt signaling [60].
Furthermore, tumor cells co-cultivated with macro-
phages display a higher invasiveness through a TNFa-
dependent MMP induction in macrophages [61]. Direct
evidence for the role of MMPs in tumor invasiveness
has been provided by many studies and cancer cells
might stimulate TAM to produce MMPs in a paracrine
manner through the secretion of various stimuli, such as
interleukins, growth factors and an extracellular matrix
metalloproteinase inducer (CD147). The invasiveness of
tumor cells is also stimulated by epidermal growth fac-
tor (EGF) synthesized by TAM in response to tumor-
derived CSF-1, leading to the induction of several genes
involved in the migration of tumor cells [62].
The leading edge of a tumor mass is the site where
TAM direct the invasion of tumor cells into host tissues.
With melanoma cells, we found that the areas of great-
est macrophage density were peritumoral [63,64], and
using a suitable in vitro model we demonstrated that
upon contact with melanoma cells, inflammatory macro-
phages express increased levels of COX-2 [64], uPAR
and MMP-9 [65]. It is also possible that MMPs secreted
by TAM can be recruited to cancer cell membranes,
and are then used as tools by the tumor cells to pro-
gress through a specific site [66]. Hiratsuka et al. (2002)
proved that MMP-9 expressed in alveolar endothelial
cells and macrophages renders the pulmonary metastatic
site fertile for secondary growth of malignant cells, a
mechanism dependent upon the activation of the VEGF-
VEGFR signaling cascade [67]. TAM also produce,
under the influence of tumor cells, the urokinase plas-
minongen activator (uPA) and receptor (uPAR), that
may cause degradation of ECM to promote invasion and
spread of tumor cells [68,69]. The uPA/uPAR system
does not only support the invasion of tumor cells, it
also modulates cell adhesion by interactions of uPAR
with vitronectin and integrins. Therefore, the uPA/
uPAR system is endowed with the structural and func-
tional properties required to promote most important
mechanisms of tumor cell migration [68,69].
Genetic experiments provide a causal link between
CSF-1-dependent TAM and malignancy in mammary
and lung cancer [70]. In particular, crossing transgenic
mice susceptible to mammary cancer and mice contain-
ing a recessive null mutation in the CSF-1 gene, Lin
et al. demonstrated that TAM are necessary for distant
organ colonization, the final step of metastatic dissemi-
nation [71].
In our laboratory, co-cultivation of tumor cells with
‘resident’ macrophages, responsive macrophages
obtained by the use of thioglycolate broth, or with ‘eli-
cited’ macrophages obtained by the use of specific infec-
tious agents (Corynebacterium parvum, BCG, Listeria
monocytogenes) enabled us to find that the number of
lung colonies detected in mice intravenously injected
with melanoma cells were greatly enhanced by co-culti-
vation of tumor cells with elicited, non-cytotoxic,
macrophages prior to injection (Figure 2) [72]. Among
the biological properties relevant to the metastatic diffu-
sion, tumor cells exposed to the macrophage-prometa-
static activity expressed increased invasiveness, an
enhanced capacity to adhere to endothelial cells and an
elevated ability to escape NK cells by increasing the
expression of MHC class I antigens [73]. This metastatic
ability of tumor cells as well as their increased invasive-
ness, adhesion and MHC expression was found to be
transient. Inflammatory cytokines, such as TNFa, con-
tribute to the pro-metastatic activity released by elicited
macrophages into their growth media [74].
Important recent studies suggest that macrophages are
recruited into the target organs and facilitate metastatic
cell seeding. Moreover, blocking macrophage lodgement
at the metastatic site limits the growth of metastatic
cells, even if metastatic lesions have readily been estab-
lished [75].
Thus, TAM are powerful tumor promoters, capable to
stimulate angiogenesis, invasiveness and subsequent
metastatic growth, but also able to set up the sites for
metastatic cell seeding.
Tumor cell - fibroblast interactions
Interactions between epithelial cells and stromal cells are
crucial in several aspects of normal development, such as
growth, differentiation and morphogenesis, but also in
pathological conditions, including tumorigenesis. A des-
moplastic or stromal reaction characterizes many inva-
sive carcinomas, for example those of the breast,
prostate, colon, lung and uterus, and several reports sug-
gest a poorer prognosis associated with carcinomas bear-
ing desmoplastic stroma [76,77]. In 1986, Dvorak
described the remarkable similarities between the reac-
tive tumor stroma and the granulation tissue present in
areas of inflammation and in tissue undergoing the remo-
delling phase of wound healing [78]. It was suggested that
granulation tissue stimulates tumor cell invasion. Dinge-
mans et al. tested this hypothesis and found that a granu-
lation tissue microenvironment, but not normal
subcutaneous stroma, elicited an invasive phenotype in
tumor cells [79]. The cascade of events leading to a gran-
ulation tissue is mainly supported by host fibroblasts, and
fibroblasts associated with wound healing as well as
reactive tumor stroma (so-called cancer-associated
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fibroblasts, CAF) are commonly identified by the expres-
sion of a-smooth muscle actin (a-SMA). This type of
cells was referred to by Gabbiani et al. as “myofibro-
blasts” [80]. Such myofibroblasts, sometimes also termed
“activated fibroblasts”, participate at all stages of tumor
progression. The agents that mediate the transition to
myofibroblasts are not yet fully elucidated. In cell culture,
myofibroblasts can be induced by transforming growth
factor-b (TGFb), either secreted by tumor cells or host
inflammatory cells [77,80]. Proteins of the extracellular
matrix produced by stromal cells with myofibroblastic
differentiation could act as a barrier against immune cells
and may regulate tumor cell behaviour by facilitating cell
contacts, motility or transport of nutrients. Moreover
myofibroblasts secrete proteins which may stimulate
tumor cell invasiveness, angiogenesis and tissue remodel-
ling [81] (Figure 3). Tumor growth and metastasis is sig-
nificantly reduced in fibroblast-deficient mice, and
injection of wild-type fibroblasts into these mice partially
reversed the observed phenotype, providing further evi-
dence for the involvement of fibroblasts in the emergence
of metastasis.
Regarding secreted factors that affect tumor cell inva-
siveness, myofibroblasts are a source of extracellular
matrix-degrading proteases such as the MMPs. In
particular, MMP-3, also known as stromelysin 1, is
highly expressed in fibroblasts/myofibroblasts and parti-
cipates in the cleavage of E-cadherin, thereby prompting
epithelial cancer cells to perform an epithelial-mesench-
ymal transition (EMT) [82]. Cancer cells undergoing
EMT loose cell-cell contacts, acquire mesenchymal
properties and develop invasive and migratory abilities.
Consequently, EMT of cancer cells is recognized as an
important determinant of tumor progression [83].
By injecting tumor cell/fibroblast cell suspension into
immunodeficent mice, Orimo et al. found that CAF iso-
lated from a human breast carcinoma and expressing a
myofibroblast phenotype, promote the growth of carci-
noma cells through a stromal cell-derived factor-1
[SDF-1]/CXCR4-dependent mechanism. These CAF did
not show aneuploidy or in vivo tumorigenic activity
[84]. Moreover, mammary carcinoma-associated fibro-
blasts stimulate a high vasculature by recruiting
endothelial progenitor cells in tumor xenografts. Thus,
SDF-1 secreted by mammary myofibroblasts may stimu-
late the growth of CXCR4-expressing carcinoma cells as
well as angiogenesis [84]. A genome analysis of the
stroma of an elevated number of invasive breast carci-
noma indicates that the hot spots for mutations in the
stroma are not the same as those identified in the
Figure 2 Change in lung-colonizing potential of B16 murine melanoma cells upon stimulation by TAM. Surface colonies (A, B) and H&E-
stained sections (C, D) of lungs collected from syngeneic animals injected with un-stimulated melanoma cells (A, C) or tumor cells stimulated by
macrophages (B, D). See the high number of metastatic lesions in lungs from animal injected with macrophage-promoted tumor cells.
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epithelium [85]. Therefore, it is possible that an inde-
pendent pathway of mutation of gene expression works
in stromal cells. Recently, Studebaker et al. showed that
IL-6 secreted by CAF enhances the growth and invasive-
ness of estrogen receptor a-positive breast carcinoma
cells through its effectors, Notch-3, Jagged-1 and carbo-
nic anhydrase IX [86].
Moreover, using an in vitro model of skin
carcinogenesis, Cat et al. [87] demonstrated that
tumor cell-derived TGF-b stimulates reactive oxygen
species-dependent expression of a-SMA in skin fibro-
blasts, and their differentiation into myofibroblasts.
This was associated with an increased release of hepa-
tocyte growth factor (HGF), VEGF and IL-6. In view of
the notion that skin fibroblasts possess a reduced capa-
city to secrete IL-6, while senescent fibroblasts strongly
up-regulate IL-6 and stimulate malignancy in epithelial
cells [88], it was suggested that CAF may represent a
subset of senescent fibroblasts. Importantly, a very
recent report demonstrates that CAF isolated from
dysplastic skin and skin carcinoma express a NF-
B-dependent proinflammatory gene signature respon-
sible for macrophage recruitment, neovascularisation,
cancer cell proliferation and invasion. This was also
manifest in CAF of mouse and human mammary and
pancreatic tumors [89].
These mesenchymal-epithelial instructive interactions
are also responsible for the integrity of the prostate
gland. Now, we know that alterations in the complex
relationship between prostate epithelial cells and stro-
mal cells contribute to the genomic instability that may
promote the progression to a malignant state of these
epithelial cells [90]. Some evidence indicates that
normal stromal fibroblasts from the fetal urogenital
sinus inhibits the in vivo growth of prostate tumor cells,
when both cell types are inoculated together. In
contrast cancer-associated stromal cells co-inoculated
with prostate cancer cells promote tumor growth
in vivo [91]. In Figure 4, tissue sections of reactive
stroma around and within a tumor mass are shown that
were obtained by the co-injection of prostate adenocar-
cinoma cells (PC3 cells) and prostate adenocarcinoma-
associated fibroblasts into immunodeficient mice.
Tumor cells are surrounded by a collagenous stroma
particularly enriched in inflammatory cells and new
microvessels (A), while collagen fibrils within the tumor
are characteristically oriented, in order to sustain the
local growth of tumor cells (B). Tuxhorn et al. have
provided some additional evidence that prostate cancer
epithelium stimulates CAF to express vimentin, a-
smooth muscle actin and calponin, which is characteris-
tic of the myofibroblast phenotype [92]. Interestingly,
initiated non-tumorigenic prostate epithelial cells co-
implanted with CAF formed tumors in immunodeficient
mice, while CAF do not affect growth of normal human
prostate epithelial cells [93].
It is possible that the most important feature in pro-
gression of prostate tumors is the ability of tumor cells
to stimulate stromal cells to release biological agents
for their growth and dissemination. Mutual interac-
tions between carcinoma cells and CAF were reported
by Nakamura et al.: tumoral IL-1, basic fibroblast
growth factor (bFGF) and platelet-derived growth fac-
tor (PDGF) stimulate HGF expression in CAF, and in
Figure 3 Some biological activities of CAF.
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turn, stromal HGF leads to an invasive phenotype in
carcinoma cells [94]. Hill et al., using a mouse model
of prostate carcinoma, showed that tumor cells upre-
gulate p53 in stromal fibroblasts, a process found to
induce a selection of a subpopulation of p53 null fibro-
blasts. In turn, selection of a p53 null subpopulation of
stromal fibroblasts contributed to the progression of
carcinoma cells [95].
The origins of CAF were revised by Orimo and Wein-
berg, who suggested three major alternative hypotheses:
a) genetic alteration, b) an activation without genetic
alteration of normal tissue fibroblasts, and c) the activa-
tion of bone marrow-derived mesenchymal stem cells
(MSC) [96]. MSC infiltrate wounds and tumors in high
numbers, and, when co-injected into immunodeficient
hosts together with weakly metastatic human breast car-
cinoma cells, they induced in these cancer cells an
increase in metastatic potential by a CCL5/CCR5-depen-
dent mechanism [97].
Despite these initial findings, additional efforts at
determining the molecular mechanisms that lead to the
appearance of differentiated fibroblasts and their multi-
ple contributions in tumor progression are still urgently
required.
Conclusions
Tumor stroma is a specialized form of tissue composed
of host cells and signals of different origin, which is
associated with tumor cell growth, primarily of epithelial
origin. Tumor stroma possesses unique structural
features that differ from the native stroma. It is also
characterised by a great degree of tumor dependency
(”There is no tumor stroma without a tumor“) and dis-
plays a substantial degree of plasticity, with the specific
outcomes controlled by tumor cells themselves. Indeed,
tumor cells do not only display heterogeneity and
induce the expression of signaling molecules that favour
their survival and invasiveness into local and distant
host tissues, but also influence host stromal elements to
produce relevant effectors that act as tumor promoters.
Moreover, tumor cell-derived signals recruit and activate
some host cells, among which monocytes/macrophages
and fibroblasts are the most abundant population within
the tumor microenvironment. As was discussed above,
both types of cells, macrophages and fibroblasts, are
involved in a intricate liaison with tumor cells, that
usually leads to tumor progression and activation of the
metastatic cascade. Thus, the investigation of the
mechanisms that allow macrophages and fibroblasts to
Figure 4 Stromal organization of a subcutaneous tumor obtained by the co-injection of prostate carcinoma cells (PC3 cells) and
“prostate-activated fibroblasts”. A desmoplastic response surrounding tumor cells rich in a neovasculature (A); and some tumor cells in a
large capillary enclosed in a dense collagenous stroma infiltrated by inflammatory cells (B) (Mallory’s trichrome). Dense collagen fibers and fine
reticular collagen bundles inside the tumor mass (C) and a high magnification of reticulin fibers within the tumor mass (D) (Gomori’s method).
(Bar 50 μm).
Calorini and Bianchini Cell Communication and Signaling 2010, 8:24
http://www.biosignaling.com/content/8/1/24
Page 7 of 10
contribute to tumor progression, could lead to new
approaches for the anti-cancer therapies that are
urgently required.
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